Bjørnarå, Kari Anne http://orcid.org/0000-0001-8898-3854
Pihlstrøm, Lasse
Dietrichs, Espen
Toft, Mathias
Funding for this research was provided by:
Vestre Viken Hospital Trust
Reberg's legacy
Norwegian Parkinson's disease Association
South-Eastern Norway Regional Health Authority
Research Council of Norway
Anna Garaas
Michael J. Fox Foundation for Parkinson's Research
Article History
Received: 12 October 2017
Accepted: 8 February 2018
First Online: 21 February 2018
Ethics approval and consent to participate
: The study was approved by the Regional Committee for Medical and Health Research Ethics in South-East Norway and all participants gave informed, written consent.
: Not applicable
: This work was supported by grants from Vestre Viken Hospital Trust, the Norwegian Parkinson’s Disease Association, Reberg’s Legacy, the Norwegian Neurological Society, Anna Garaas, South-Eastern Norway Regional Health Authority and the Research Council of Norway. PPMI is sponsored and partially funded by the Michael J. Fox Foundation for Parkinson’s Research (MJFF). Other funding partners include a consortium of industry players, non-profit organizations and private individuals, including Abbott, Avid, Biogen Idec, Covance, Elan, GlaxoSmithKline, Lilly, Merck, UCB, F. Hoffman-La Roche Ltd., GE Healthcare, Genentech, and Pfizer Inc. Industry partners are contributing to PPMI through financial and in-kind donations and are playing a lead role in providing feedback on study parameters through the Industry Scientific Advisory Board (ISAB). For up-to-date information on the study, visit ExternalRef removed. The funders had no role in study design, collection, analysis and interpretation of data, writing of the article or the decision to submit the article for publication. The authors declare that they have no competing interests.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.